Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (374)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (13)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (298)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 51 to 100 of 384
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370
Technology appraisal guidance
TBC
Cardiometabolic disease prevention and treatment guidelines
NICE guideline
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Technology appraisal guidance
23 October 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure
NICE guideline
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Technology appraisal guidance
TBC
Cladribine for treating relapsing multiple sclerosis ID6263
Technology appraisal guidance
5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment
Health technology evaluation
TBC
Colon cancer (adjuvant) - irinotecan [ID379]
Technology appraisal guidance
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
Technology appraisal guidance
30 October 2024
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Diagnostics guidance
10 July 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]
Technology appraisal guidance
29 May 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]
Technology appraisal guidance
17 July 2024
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
DCVax-L for treating glioblastoma [ID836]
Technology appraisal guidance
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897
Technology appraisal guidance
TBC
Diabetic retinopathy
NICE guideline
TBC
Diabetic retinopathy - ruboxistaurin [ID382]
Technology appraisal guidance
TBC
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment
Health technology evaluation
15 August 2024
Digitally enabled therapy for chronic tic disorders and Tourette Syndrome
Medical technologies guidance
19 December 2024
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants
Interventional procedures guidance
13 November 2024
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Technology appraisal guidance
11 September 2024
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Technology appraisal guidance
TBC
Drug eluting stents for treating coronary heart disease: late stage assessment
Health technology evaluation
TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
Technology appraisal guidance
TBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]
Technology appraisal guidance
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
NICE guideline
TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Technology appraisal guidance
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Technology appraisal guidance
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317
Technology appraisal guidance
TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725
Technology appraisal guidance
TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Technology appraisal guidance
TBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)
NICE guideline
31 March 2025
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
Technology appraisal guidance
TBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Technology appraisal guidance
24 July 2024
Previous page
1
Current page
2
3
4
…
8
Page
2
of
8
Next page
Results per page
10
25
50
All
Back to top